Proton pump inhibitors (omeprazole representative)

Proton pump inhibitors block the gastric H⁺/K⁺-ATPase, the final step in acid secretion. That is downstream of histamine’s action at the H2 receptor on parietal cells, and further downstream still from the mast cell — the drug does not act on the cell, and blocking acid production is a different intervention from blocking a mediator at its receptor, which is what an H2 antihistamine does.

They appear here because patient-facing mast cell resources list them, including the medication list published by The Mast Cell Disease Society, where they are grouped for reflux rather than presented as mast-cell therapy. Reflux is common alongside mast cell activation, and a page that omitted a whole class patients are routinely prescribed would be incomplete in a way that matters more than tidiness.

There is one mast-cell finding worth recording honestly. A 2021 mouse study reported that omeprazole inhibited IgE-mediated mast cell activation, measuring degranulation, cytokine release, and signalling through the high-affinity IgE receptor. The authors framed it around the observation that acidity inside mast cell granules matters for how those cells behave. It is a mechanism worth knowing about and it is not a result in people.